International Clinical Trial: Alpaglitovirizumab (QL1706) combined with chemotherapy for late stage treatment A single arm, open, multicenter neoadjuvant therapy for endometrial cancer Phase II clinical study

Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132330) titled 'Alpaglitovirizumab (QL1706) combined with chemotherapy for late stage treatment A single arm, open, multicenter neoadjuvant therapy for endometrial cancer Phase II clinical study' on Sept. 11.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Fujian Cancer Hospital

Condition: Endometrial cancer (including endometrioid carcinoma, serous carcinoma, clear cell carcinoma, dedifferentiated/undifferentiated carcinoma, mixed carcinoma, carcinosarcoma, etc.) Endometrial cancer at stage III to IVB, after assessment, is found to be intolerant to surgery or unsatisfactory for tumor reduction....